Insights into the therapeutic outcomes of trimetazidine/doxorubicin combination in Ehrlich solid-phase carcinoma mouse tumor model
Abdeljalil, Somaya M; Wahdan, Sara A; Elghazaly, Hesham; Tolba, Mai;
Abstract
One of the key features of cancer is metabolic reprogramming that can be exploited to sensitize cancer cells to chemotherapy. Trimetazidine (TMZ) is a metabolic anti-ischemic drug that blocks the activity of long-chain 3-ketoacyl CoA thiolase leading to the inhibition of fatty acid oxidation.
Other data
| Title | Insights into the therapeutic outcomes of trimetazidine/doxorubicin combination in Ehrlich solid-phase carcinoma mouse tumor model | Authors | Abdeljalil, Somaya M; Wahdan, Sara A; Elghazaly, Hesham; Tolba, Mai | Keywords | Apoptosis;;Trimetazidine;Metabolic reprogramming;Doxorubicin;;Breast cancer | Issue Date | 1-Sep-2023 | Journal | Life sciences | Volume | 328 | ISSN | 00243205 | DOI | 10.1016/j.lfs.2023.121874 | PubMed ID | 37352914 | Scopus ID | 2-s2.0-85164296002 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.